Project Grant R44CA291419
Award Date
2/1/25
Completion Date
1/31/27
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports the development of a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. Radiopharmaceutical Imaging And Dosimetry, LLC will receive $898,497 over the project period from August 2024 to July 2026 to implement a macro-to-micro (M2M) dosimetry methodology that derives microscale activity...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $811,503 Project Grant under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program to Qscint Imaging Solutions LLC in Tucson, AZ. The grant supports the development of an innovative radiation imaging tool that allows researchers and radiopharmaceutical developers to visualize the spatial distribution and isotopic composition of targeted alpha...
This $644,622 Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to enhance the efficacy of radioligand therapy for metastatic castrate-resistant prostate cancer. The key products and services to be delivered include: Developing a novel method for bone marrow dosimetry by coupling macro/micro Monte Carlo modeling with imaging data on lesion and marrow distribution in spongiosa. Building predictive models to forecast absorbed...
This Project Grant award of $581,723 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the development of a novel imaging system called "Alpha-Scope" at The Johns Hopkins University. The Alpha-Scope will utilize advanced detector hardware and a synthetic compound eye gamma camera design to provide ultrahigh-sensitivity, high-resolution 3D autoradiography of radiopharmaceuticals and their radioactive daughter products in small animal models....
This $627,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to optimize radioligand therapy dosimetry and kidney biomarkers for alpha-emitter radiotherapy in neuroendocrine tumors. The key products and services to be delivered include: Developing a detailed understanding of the role of superoxide dismutation in tubular DNA repair following alpha-emitter radiotherapy Identifying optimal dosing regimens of the [212Pb]Pb-VMT-A-NET...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based models for personalizing radiopharmaceutical therapy (RPT) treatment planning for metastatic castration-resistant prostate cancer (mCRPC). The key products and services to be delivered under this 5-year award (1/1/2025 - 12/31/2029) include: Building predictive models of 177Lu-PSMA dosimetry using imaging data from PSMA-PET...
The General Hospital Corporation (doing business as Massachusetts General Hospital) was awarded a $422,508 Project Grant from the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The funding will support the development of a new reverse Monte Carlo software for Single Photon Emission Computed Tomography (SPECT) reconstruction. The software will be built from scratch on a GPU platform to speed up simulations, with the goal of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $799,962 to Tripill Biotechnology, Corp. to develop and validate radiolabeled PSMA agents with reduced salivary gland uptake for the improved imaging and treatment of prostate cancer. The key objectives are to construct PSMA derivatives that can selectively reduce radiation exposure to normal organs, such as the salivary glands, while maintaining high tumor uptake. Preliminary...
The National Cancer Institute (NCI) awarded a $644,034 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a nanoparticle-based drug delivery platform that uses radiation to control the release of chemotherapy payloads within irradiated tumor tissue. The project aims to expand the therapeutic window of chemoradiation by improving local disease control while mitigating...
This Project Grant award of $662,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery. The key research objectives are: Quantify how local radiation reshapes the tumor microenvironment to impact passive drug delivery in mouse and patient-derived cancer models, using in vivo imaging, multiplexed microscopy, and functional perturbations. Test whether...